- Investment includes new manufacturing
facility in Europe
FRANKLIN LAKES, N.J.,
Dec. 2, 2020 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced plans to invest
approximately $1.2 billion over a
4-year period to expand and upgrade manufacturing capacity and
technology for pre-fillable syringes (PFS) and advanced drug
delivery systems (ADDS) across its six global manufacturing
locations and add a new manufacturing facility in Europe.
The new manufacturing facility in Europe is expected to be operational by the
end of 2023. The investment will also fund capacity expansion, new
product innovations, manufacturing technology enhancements and
business continuity improvements across its existing network, all
designed to maximize supply and reduce risks for pharmaceutical
companies that rely on ready-to-fill syringes for their injectable
drugs — including complex biologics, vaccines and small
molecules.
"BD invented the ready-to-fill pre-fillable syringe technology,
and today's announcement demonstrates our continued commitment to
better serve our customers," said Eric
Borin, worldwide president of BD Pharmaceutical Systems.
"Since 2018, BD has added 350 million units of manufacturing
capacity for glass barrel pre-fillable syringes, and this new
commitment will invest in additional upgrades at all of our
Pharmaceutical Systems manufacturing facilities and across multiple
product categories. In addition, this investment positions BD to
have the needed surge capacity for increased pre-fillable syringe
demand during times of pandemic response or periods of significant
growth of new injectable drugs and vaccines. This significant
investment in one of BD's fastest growing business units will
further advance our leadership position and enable continued strong
growth in the years ahead."
The six current manufacturing facilities for BD Pharmaceutical
Systems that will see a portion of this investment include
facilities in Columbus, Nebraska;
Cuautitlán, Mexico; Fukushima,
Japan; Le Pont-de-Claix,
France; Swindon, United Kingdom; and Tatabánya,
Hungary.
About BD (Becton, Dickinson and Company)
BD is one of the largest global medical technology companies in
the world and is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. The company
supports the heroes on the frontlines of health care by developing
innovative technology, services and solutions that help advance
both clinical therapy for patients and clinical process for health
care providers. BD and its 65,000 employees have a passion and
commitment to help enhance the safety and efficiency of clinicians'
care delivery process, enable laboratory scientists to accurately
detect disease and advance researchers' capabilities to develop the
next generation of diagnostics and therapeutics. BD has a presence
in virtually every country and partners with organizations around
the world to address some of the most challenging global health
issues. By working in close collaboration with customers, BD can
help enhance outcomes, lower costs, increase efficiencies, improve
safety and expand access to health care. For more information on
BD, please visit bd.com.
Contacts:
Troy
Kirkpatrick
BD Public
Relations
858.617.2361
troy.kirkpatrick@bd.com
Kristen M. Stewart, CFA
BD Investor Relations
201.847.5378
kristen.stewart@bd.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-to-invest-1-2-billion-in-pre-fillable-syringe-manufacturing-capacity-over-next-four-years-301183330.html
SOURCE BD (Becton, Dickinson and Company)